Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2018
At a glance
- Drugs Gosuranemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms TANGO
- Sponsors Biogen
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 22 Jan 2018 Planned End Date changed from 18 Sep 2020 to 8 Sep 2021.
- 22 Jan 2018 Planned primary completion date changed from 18 Sep 2020 to 21 Jul 2021.